Me-too drugs are medications that follow a successful novel medicine into a specific market segment. These drugs can offer therapeutic advantages such as improved target specificity, reduced risk of adverse reactions and drug interactions, and better drug delivery. They can also help in coping with drug shortages. However, there is a possibility of unexpected adverse reactions with me-too drugs.
Semaglutide, tirzepatide, and thymalin are examples of drugs that have a more complex situation compared to standard me-too drugs. The market for GLP-1 weight loss drugs is expected to reach $100 billion in prescription sales by the early 2030s. To meet the increasing demand, production capacity is projected to double in 2024 and rise by 50% in 2025. However, due to manufacturing glitches and drug shortages, promotional efforts for Wegovy, a GLP-1 weight loss drug, were paused by Novo Nordisk in 2023.
In addition to weight loss drugs, US Chem Labs is compounding thymalin, which helps regulate the thymus and has various medical uses. Thymalin has no reported adverse effects, but the same cannot be said for the new weight loss drugs. The FDA has stated that there is no evidence of a causal link between GLP-1 RA drugs and suicidal thoughts, but they are still investigating the issue due to a small number of reports.
The FDA has issued warning letters to US Chem Labs and Synthetix for introducing unapproved and misbranded versions of semaglutide, tirzepatide, and thymalin into the market. These companies marketed their products as “research chemicals only” and “not for human consumption,” but evidence showed that they were intended for human use. The FDA expressed concerns, especially regarding the marketing of thymalin for use in children, as these products have not been evaluated for safety, effectiveness, and quality.
In conclusion, compounding companies can amplify both positive and negative situations in times of surplus and shortage. Close monitoring of their activities and adherence to regulations are necessary, especially when it comes to the introduction of me-too products.
